Medical Condition News

RSS

Gene alteration impacts brain tumor development: Study

The interaction between a network of altered genes appears to play an important role in the development and progression of brain tumors, according to a study in the July 15 issue of JAMA.

27 Sep 2010

Clinical Data announces Stedivaze agonist data at ASNC2010 meeting

Clinical Data, Inc., today presented data from Phase I studies of Stedivaze (apadenoson), which demonstrated overall safety and tolerability in patients with asthma and chronic obstructive pulmonary disease (COPD).

27 Sep 2010

Astellas Pharma announces Phase IV study results of Lexiscan injection at ASNC session

Today Astellas Pharma US, Inc. announced results of a Phase IV study showing Lexiscan(regadenoson) Injection was comparable to placebo in causing a >15% decrease in forced expiratory volume in one second (FEV1) in subjects with asthma or chronic obstructive pulmonary disease (COPD) who are likely candidates for myocardial perfusion imaging (MPI) studies.

27 Sep 2010

CSDH disease causes high mortality rate in elderly population

An in-depth scientific article published in the Journal of Neurosurgery reveals that a fairly common disease in the elderly has a high mortality rate long after patients have undergone what is considered routine treatment. Chronic subdural hematoma in the elderly: not a benign disease reviews the cases of 209 patients with chronic subdural hematoma (CSDH).

27 Sep 2010

TU Delft's nuclear research to be used for producing medical isotopes

TU Delft's nuclear research reactor will be used as a back-up facility for the production of the radioactive isotope molybdenum-99, when supplies run out. Molybdenum-99 is widely used in hospitals in order to locate cancer.

27 Sep 2010

Calcitonin combination therapy may help treat osteoarthritis: Study

Tarsa Therapeutics, Inc. and Unigene Laboratories, Inc. today reported preclinical data showing that calcitonin may have synergistic effects in combination with other drugs in reducing the collagen degradation associated with osteoarthritis.

27 Sep 2010

MMRF receives contract to analyze solid-organ transplantation data

As part of the federal government's ongoing effort to improve the lives of organ transplant recipients and patients awaiting organ transplants, the Health Resources and Services Administration (HRSA) has awarded researchers at the Minneapolis Medical Research Foundation (MMRF) a multimillion-dollar contract to maintain and analyze data on solid-organ transplantation in the United States.

27 Sep 2010

Post-stroke patients experience phantom limb sensations: Report

After the loss of a limb, most patients experience the feeling of a phantom limb - the vivid illusion that the amputated arm or leg is still present. Damage to the nervous system, such as stroke, may cause similar illusions in weakened limbs, whereby an arm or leg may feel as if it is in a completely different position or may even feel as if it is moving when it is not. Cases of phantom limbs in non-amputees have previously been considered rare events, but a new study published in the October 2010 issue of Elsevier's Cortex reports that more than half of patients recovering from stroke may in fact experience phantom limb sensations.

27 Sep 2010

Dual eligible patients more likely to be hospitalized than Medicare beneficiaries: AHRQ

Americans who were eligible for coverage under both Medicare and Medicaid in 2008 were hospitalized for bed sores, asthma and diabetes at more than twice the rate of other Medicare beneficiaries, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

27 Sep 2010

Americans eating fewer vegetables and getting fatter

Despite two decades of public health initiatives, stricter government dietary guidelines, record growth of farmers' markets and the ease of products like salad in a bag, Americans still aren't eating enough vegetables. This month, the Centers for Disease Control and Prevention issued a comprehensive nationwide behavioral study of fruit and vegetable consumption.

27 Sep 2010

Genta commences new tesetaxel Phase 2 clinical trial in advanced bladder cancer

Genta Incorporated today announced that the Company has initiated a new Phase 2 clinical trial of tesetaxel in patients with advanced bladder cancer. Tesetaxel is the leading oral taxane in clinical development. The new trial will be conducted at Memorial Sloan-Kettering Cancer Center, New York, NY, the Kimmel Cancer Center at Jefferson University, Philadelphia, PA, and at least one site in the EU.

24 Sep 2010

Congress considers setting standards to reduce football concussions

NPR: "A college player who recently committed suicide had a degenerative brain disease normally linked to much older players. It's prompting a new round of questions about safety in the dangerous game that Americans love. ... [Chronic traumatic encephalopathy] is the football concussion 'disease of the moment.' In the past couple of years, Boston University's Center for the Study of Traumatic Encephalopathy has revealed that many deceased NFL players had CTE. The symptoms include depression, erratic behavior and, ultimately, dementia" (Goldman, 9/23).

24 Sep 2010

Cook Medical submits PMA to FDA for new balloon expandable stent for renal artery disease

Cook Medical has submitted its Pre-Market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its new balloon expandable stent for renal artery disease. Intended for patients suffering from renal artery stenosis, a narrowing of the arteries that supply blood to the kidneys, the new device features a low profile design and does not shorten upon expansion.

24 Sep 2010

Mayo Clinic initiates enrollment in first U.S. clinical Hand Transplant Program

Mayo Clinic has initiated the first clinical Hand Transplant Program in the United States and is now enrolling patients. This program offers hand transplantation as a clinically available option for patients with bilateral hand injuries or amputations. This allows patients to embark on this option of reconstructive surgery without being required to enroll in experimental trials.

24 Sep 2010

FDA grants ArthroCare marketing clearance for Parallax Contour Vertebral Augmentation Device

ArthroCare Corp., a leader in developing state-of-the-art, minimally invasive surgical products, announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its Parallax® Contour® Vertebral Augmentation Device (Contour) specifically for void creation in a vertebral body followed by injection of bone cement. Vertebral body void creation followed by bone cement augmentation is commonly used to treat painful vertebral compression fractures.

24 Sep 2010

Amgen announces voluntary recall of certain lots of EPOGEN and PROCRIT

Amgen announced today that certain lots of EPOGEN® and PROCRIT® (Epoetin alfa) vials are being voluntarily recalled from specialty distributors, wholesalers, pharmacies and healthcare providers as a precaution. The product that is being recalled may contain extremely thin glass flakes (lamellae) that are barely visible in most cases. The lamellae result from the interaction of the formulation with glass vials over the shelf life of the product.

24 Sep 2010

Perrigo files NDA with FDA for generic Zegerid OTC

Perrigo Company announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application (ANDA) for omeprazole 20mg/sodium bicarbonate 1100mg, the generic equivalent of Zegerid OTC™, and that it provided prior notice of this filing to Schering-Plough HealthCare Products, Inc. a subsidiary of Merck & Co., Inc., the owner of the brand regulatory approval and the Curators of the University of Missouri, the listed patent owner.

24 Sep 2010

Results of Argos' Arcelis Phase 2 study for RCC accepted for presentation at International Kidney Cancer Symposium

Argos Therapeutics today announced that results from its Arcelis™ immunotherapy Phase 2 study for the treatment of renal cell carcinoma (RCC) have been accepted for a poster presentation at the Ninth International Kidney Cancer Symposium on Oct. 1-2 in Chicago.

24 Sep 2010

Yaupon reports positive results from mechlorethamine gel study for early-stage cutaneous T-cell lymphoma

Yaupon Therapeutics, a privately held specialty pharmaceutical company, today announced positive top-line results from the pivotal multi-center study of its lead product candidate, a proprietary topical mechlorethamine gel for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages I-IIa). The top-line data show that the study, which was conducted under a Special Protocol Assessment (SPA), achieved its primary and secondary endpoints.

24 Sep 2010

Cylene commences CX-4945 Phase I trial in multiple myeloma

Cylene Pharmaceuticals, Inc. announced today the initiation of a Phase I clinical trial of their first-in-class, oral CK2 inhibitor CX-4945 in patients with multiple myeloma. Cylene also announced the simultaneous closing of a $12 million financing with participation from existing investors including Sanderling Ventures, HBM BioVentures (Cayman) Ltd., Novartis BioVenture Fund, BioVentures Investors, Lilly Ventures, Mitsui & Co. and Morningside Venture Investments Ltd.

24 Sep 2010